Cannabics Pharmaceuticals Inc.

Pharmacy Market

Businesswire | June 30, 2023

NanoTemper Technologies, creator of biophysical tools for drug discovery, today, proudly announced the launch of their highly anticipated Biotinylated Target Labeling Kit, expanding the molecular interaction analysis toolkit for scientists working with complex or undruggable targets, filling a vital gap in screening and hit validation workflows in the pharma industry. This new kit combined with NanoTemper’s exclusive Spectral Shift technology is the preferred orthogonal me...

VIEWS AND ANALYSIS, PHARMA TECH

Novavax, Inc. | December 16, 2022

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027. The notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In connection with the offering of the notes, No...

Pharma Tech

Gerresheimer AG | August 18, 2022

Gerresheimer AG and Zollner Elektronik AG are pooling their market-leading pharmaceutical and medical technology expertise under a strategic partnership. Starting immediately, they will offer pharmaceutical, healthcare and biotech companies their conceptual design, development and manufacturing capacities for drug delivery and medical technology systems, including complete electronics, from one single source. Gerresheimer serves as the central point of contact for customers. The market-leading p...

Pharmacy Market

Eagle Pharmaceuticals, Inc. | March 29, 2022

Eagle Pharmaceuticals, Inc. reported that it had achieved an agreement with Acacia Pharma Group plc on the parameters of a plan of arrangement under Part 26 of the United Kingdom's Companies Act 2006. Acacia Pharma's current issued and to be issued, share capital is valued at approximately €94,700,000, or the equivalent of €0.90 per share, under the terms of the proposed transaction. Each Acacia Pharma shareholder would get €0.68 in cash and 0.0049 shares of...